Skip to main content
. 2023 May 18;60:101993. doi: 10.1016/j.eclinm.2023.101993

Fig. 2.

Fig. 2

Use of therapeutic or preventive treatments for bone-marrow suppression (n = 1465). (A) After start of radium-223 treatment in patients who did or did not receive prior chemotherapy. (B) After completion of radium-223 treatment in patients who did or did not receive subsequent chemotherapy. aPatients may have received chemotherapy at other times.